Organogenesis Holdings Inc. (ORGO) jumped 53.72% to $5.98, up $2.09, after reporting strong third-quarter 2025 results and revising its full-year outlook.
The company posted $150.5 million in net product revenue, up 31 percent year-over-year, driven by Advanced Wound Care, up 31 percent, and Surgical & Sports Medicine, up 25 percent.
Net income reached $21.6 million, or $0.11 per share, versus $12.3 million and $0.09 per share in the year-ago period; adjusted EBITDA rose to $30.1 million, more than double the prior year.
For full-year 2025, the company raised guidance: expecting $500 million-$525 million in net product revenue, a 4-9 percent growth, and adjusted EBITDA of $45.5 million-$68.3 million.
On the earnings day, ORGO's volume spiked as the market reacted to the beat and guidance bump. The stock's 52-week range is approximately $2.61 - $6.71.
For comments and feedback contact: editorial@rttnews.com
Business News
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.